Additionally, since there is an increasing amount of data indicating that the reduction of Aβ plaques in AD patients does not improve clinical symptoms, it is possible that clusterin’s inhibition of OPC differentiation, as described here, may be one of the mechanism though which increased levels of clusterin might contribute to AD progression[58]. This evidence concerns the gene CLU and Alzheimer disease.